ANGPTL4 & Adipose RNA Update

Ethan Weiss
  • 0.0 (0)
  • Life Sciences
  • Updated Weekly

Weekly digest of ANGPTL4 biology/therapeutics and adipose-targeted RNA delivery (siRNA, ASO, LNP, GalNAc).

  1. 5d ago

    ANGPTL4 & Adipose RNA Update — Monday August 17, 2026

    The week's strongest signal is a Molecular Therapy paper using antibody-targeted lipid-coated nanoparticles to deliver siRNA into a specific pathogenic adipose stromal cell population — a concrete adipose-RNA-delivery advance — alongside a cluster of new mechanistic data tying ANGPTL4 to cancer metastasis, immune evasion, and renal fibrosis, plus a registered systematic-review protocol on ANGPTL3/ANGPTL4/APOC3 inhibitors for hypertriglyceridemia-driven pancreatitis.

  2. Aug 10

    ANGPTL4 & Adipose RNA Update — Monday August 10, 2026

    A thin week for ANGPTL4-specific literature — every ANGPTL4 hit in the 8-day PubMed window duplicated prior coverage — but three adjacent papers are worth a look: two on adipocyte differentiation mechanisms and one on an siRNA nanovesicle delivery platform.

  3. Aug 3

    ANGPTL4 & Adipose RNA Update — Monday August 3, 2026

    The strongest new finding this week ties ANGPTL4 directly to podocyte lysosomal dysfunction in diabetic kidney disease, while a second paper reinforces ANGPTL4's role in tumor immune evasion — together they widen the therapeutic rationale for ANGPTL4 inhibition beyond lipid metabolism; no new adipose-tropic RNA delivery platform papers surfaced this week.

  4. Jul 27

    ANGPTL4 & Adipose RNA Update — Monday July 27, 2026

    A quiet week for the core beat — no new adipose-targeted RNA delivery papers and no new patents, but two ANGPTL4 biology papers stand out: a new placental biomarker study in gestational diabetes and a review reaffirming ANGPTL4's place in the causal triglyceride-ASCVD pathway.

  5. Jul 20

    ANGPTL4 & Adipose RNA Update — Monday July 20, 2026

    No new adipose-targeted RNA delivery papers turned up this week, but three fresh papers deepen the case for ANGPTL4 as a disease-driving signal outside classic lipid metabolism — in sleep-linked metabolic risk, cholangiocarcinoma metastasis, and colorectal cancer's tumor microenvironment.

  6. Jul 13

    ANGPTL4 & Adipose RNA Update — Monday July 13, 2026

    A new review makes the clinical case for ANGPTL-axis therapeutics in dyslipidemia, while two mechanism papers add fresh evidence that ANGPTL4 drives drug resistance and inflammation in solid tumors — no adipose-targeted RNA delivery papers surfaced this cycle.

  7. Jul 6

    ANGPTL4 & Adipose RNA Update — Monday July 6, 2026

    Three new mechanistic papers this week converge on ANGPTL4 as a secreted signal that drives fibrosis and immune evasion outside its classic lipid-metabolism role — in kidney, liver tumor stroma, and now the blood-brain barrier — while no new adipose-targeted RNA-delivery papers or patents cleared the bar.

  8. Jun 29

    ANGPTL4 & Adipose RNA Update — Monday June 29, 2026

    A thin but focused week — ANGPTL4 surfaces in a gut-microbiome/adipose crosstalk review and in a mechanistic study linking YAP condensates to proangiogenic ANGPTL4 expression, while an adipocyte cell-death study employs adipocyte-specific siRNA to implicate caspase-8 in adipogenesis.

See All (18)

About

Weekly digest of ANGPTL4 biology/therapeutics and adipose-targeted RNA delivery (siRNA, ASO, LNP, GalNAc).

Information

  • Creator
    Ethan Weiss
  • Years Active
    2026
  • Episodes
    18
  • Rating
    Clean
  • Copyright
    © Ethan Weiss / Marea Therapeutics
  • Show Website
    ANGPTL4 & Adipose RNA Update